Phosphate Study – IMPHOS http://imphos.org/ Mon, 21 Nov 2022 12:05:44 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://imphos.org/wp-content/uploads/2021/08/IMPHOS-icon-150x150.jpg Phosphate Study – IMPHOS http://imphos.org/ 32 32 Unicycive Therapeutics, Inc (UNCY) Reports Key UNI-494 Findings https://imphos.org/unicycive-therapeutics-inc-uncy-reports-key-uni-494-findings/ Mon, 21 Nov 2022 12:05:44 +0000 https://imphos.org/unicycive-therapeutics-inc-uncy-reports-key-uni-494-findings/ News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here. Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings from a preclinical study in animal models of geographic atrophy (GA) on […]]]>

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.


Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings from a preclinical study in animal models of geographic atrophy (GA) on the effectiveness of UNI-494.

UNI-494 is a mitochondrial potassium channel activator (mitochondrial KATP) in development for the treatment of diseases affected by mitochondrial dysfunction, such as kidney, liver and eye diseases. Mitochondrial dysfunction is implicated in the progression of age-related macular degeneration (AMD). GA is an advanced form of AMD. The Company evaluated the effect of UNI-494 in preventing loss of visual function in a rat model of knee OA.

The study evaluated four groups (n=8 per group): untreated control, vehicle, low dose UNI-494 and high dose UNI-494. AG has been induced by bilateral subretinal injection of sodium iodate in laboratory animals. UNI-494 was administered orally twice daily (BID) for 20 days, with the first administration of UNI-494 starting before the sodium iodate injection. Contrast vision was measured by optokinetic monitoring. Treatment of animals with the high dose of UNI-494 resulted in 150% and 200% improvement in contrast vision compared to vehicle and untreated animals. Further preclinical studies are planned to investigate these promising findings on the effect of UNI-494 in improving visual function.

“We are delighted to report that UNI-494 improved visual function in well-established rat models of AI, which is responsible for 10-20% of blindness in AMD, a disease that affects five million people. in the world. Contrast sensitivity is widely accepted as a critical aspect of visual function and has been shown to correlate with the ability to perform instrumental activities of daily living,” said Shalabh Gupta, MD, CEO of Unicycle.

“Importantly, these data support the mechanism of action of UNI-494, which holds promise for indications in which mitochondrial dysfunction is involved, such as kidney disease, liver disease and others. ophthalmic diseases. Our goal is to stay focused and advance UNI-494 in kidney disease, and explore partnerships for other indications to maximize the potential of this promising new therapeutic. To that end, we remain on track to initiate a Phase I study in healthy volunteers in the first quarter of 2023 in the UK following clearance from the Medicines and Healthcare Products Regulatory Agency ( MHRA),” Dr Gupta concluded.

About UNI-494

UNI-494 is a new patented drug that selectively binds and activates the SUR2B subunit of the mitochondrial KATP channel to restore mitochondrial function and reduce oxidative stress. UNI-494 is cleaved by esterase enzymes to form nicorandil, the active metabolite. Nicorandil has extensive safety and efficacy data from multiple clinical trials including a randomized controlled trial of 5,000 patients (IONA study) and there is consensus in the literature that mitoKATP channel activation is the biological basis of cardio-protection and reno-protection in several clinical trials.

Unicycive has completed all non-clinical safety evaluation studies required for regulatory filing to initiate a Phase I study in healthy volunteers. The Company is on the right track to launch the phase I study on healthy volunteers.

UNI-494 is protected by issued patents in the United States and Europe and a wide range of patent applications worldwide.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing new treatments for kidney disease. Unicycive’s lead drug, Renazorb, is a new phosphate-binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Forward-looking statementCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as “anticipate”, “believe”, “expect”, “estimate”. ‘ and ‘intend’. ” or other similar words or expressions that relate to Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. Many factors could cause cause actual events to differ materially from those indicated by these forward-looking statements.These factors include, but are not limited to, clinical trials involving a long and expensive process with an uncertain outcome, and the results of studies and prior trials may not be predictive of future trial results; our clinical trials may be suspended or terminated due to unexpected side effects or other safety risks that may prevent approval of our product candidates; risks related business interruptions, including the COVID-19 coronavirus outbreak, which could seriously harm our business financial situation and increase our costs and expenses; reliance on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence on third parties; and risks related to the inability to obtain FDA clearances or approvals and non-compliance with FDA regulations. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including: uncertainties related to market conditions and other factors described in more detail in the section entitled “Risk Factors” of the annual report of Unicycive on Form 10-K for the fiscal year ended December 31, 2021 and other periodic reports filed with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or other.

Investor contacts:

[email protected](650) 900-5470

Anne Marie FieldsStern Investor Relations [email protected]212-362-1200

SOURCE: Unicycive Therapeutics, Inc.

main logo

Source: Unicycive Therapeutics, Inc.

]]>
This Week at the FDA: Califf and Pazdur Back in Power, Accelerated Approval, and More https://imphos.org/this-week-at-the-fda-califf-and-pazdur-back-in-power-accelerated-approval-and-more/ Fri, 18 Nov 2022 22:08:16 +0000 https://imphos.org/this-week-at-the-fda-califf-and-pazdur-back-in-power-accelerated-approval-and-more/ Welcome to another episode of This Week at FDA, your weekly source for updates — big and small — about the FDA, drug and medical device regulation, and what we’re reading on the web. This week, we heard from FDA Commissioner Robert Califf and Director of the Oncology Center of Excellence (OCE) Richard Pazdur about […]]]>
Welcome to another episode of This Week at FDA, your weekly source for updates — big and small — about the FDA, drug and medical device regulation, and what we’re reading on the web. This week, we heard from FDA Commissioner Robert Califf and Director of the Oncology Center of Excellence (OCE) Richard Pazdur about plans to return to the FDA office, expedited approvals, and a new initiative called Project Pragmatica.

The FDA’s Cardiovascular and Kidney Drug Advisory Committee this week recommended that the agency approve Ardelyx’s chronic kidney disease drug tenapanor, both alone and in combination with phosphate binders, Endpoints reports.

The agency also warned seven companies for marketing dietary supplements to treat various cardiovascular diseases. Some of the offending products were listed on Amazon and Walmart, while others were marketed on social media or directly on company websites. “Because cardiovascular disease is the leading cause of death in the United States, it is important that the FDA protect the public from products and companies that illegally claim to treat it,” said Cara Welch, director of the Office of Dietary Supplement Programs within the Center for Food Safety and Applied Nutrition.

Reuters reports that the World Health Organization (WHO) is negotiating rules to manage pandemics in the future. The rules would be legally binding on members of the international health body, if adopted, and could include provisions requiring drugmakers to disclose drug pricing information in agreements with governments about products made. for future pandemics.

Medicines and biologicals

Earlier this week, the FDA took a first step toward easing access to the opioid overdose drug naloxone by issuing a notice saying it believes low-dose versions of the drug could be safe and effective for over-the-counter use.

On Thursday, the FDA released its latest quarterly batch of product-specific guidelines (PSGs) to facilitate the development of various generic drugs. The FDA said the batch includes 29 new PSGs and 22 revised PSGs, including 28 for complex products, including 11 that have no generic competition.

The agency also granted several notable approvals this week, including Provention Bio’s Tzield (teplizumab-mzwv) as the first drug cleared to delay the onset of type 1 diabetes, Immugen’s Elahere (mirvetuximab soravtansine-gynx) to treat platinum-resistant ovarian cancer, and Eli Lilly’s Rezvoglar (insulin glargine-aglr) as a second interchangeable biosimilar insulin product.

The FDA recently updated two policy and standard operating procedure documents: SOPP 8403: Voluntary Issuance, Reissuance, and Revocation of Biologics Licenses and SOPP 8405.1: Procedures for Resubmission to an Application or Supplement.

Additionally, we have learned that the FDA has completed work on a guide to homeopathic products. The guidance is currently being submitted to the Office of Management and Budget for review and may be released shortly.

medical technology

The FDA announced a public workshop on Dec. 7 that will focus on the appropriate use of consensus standards in premarket medical device submissions.

The FDA this week issued Roche an emergency use authorization (EUA) for its high-throughput monkeypox test. The cobas MPXV test works with the cobas 6800/8800 systems from Roche.

Califf and Pazdur Talk Return to Power, Fast-Track Approvals and Project Pragmatica

In a candid discussion at the Friends of Cancer Research (FOCR) annual meeting in Washington, D.C. on Thursday, Califf and Pazdur shared their expectations for the agency’s work model after more than two years of operation in a predominantly virtual environment.

“One thing I miss now, compared to 2016, is that I used to walk around the FDA, and you would just see rooms of people looking at data, trying to figure out what it means. “, explained Califf. “We are here in person now. If you walk around White Oak right now, there’s a lot of empty space… We’re now coming to the point of deciding what we’re going to do to get back to office and some members of Congress have strong opinions about that . ”

“Free space? The place is deserted,” Pazdur joked, noting that he expects the agency to maintain a hybrid work model “with great flexibility” going forward.

Califf said the agency was finalizing plans to return to the office, but “nobody I know is saying 100% of people should be there like the good old days,” and cited job satisfaction and productivity as benefits. remote work. But, Califf said, “the expectations of the industries that we regulate — we’ve heard loud and clear that they want in-person meetings, so there will be that component.”

Regarding expedited approvals, Pazdur said the agency is really interested in seeing companies present a “full plan on what their confirmatory study is” when they come to the agency to discuss an earlier approval. While he said big companies often buy into this, he said “where we get into trouble is…with a pharmaceutical company that may not be capitalized enough.” [that] wants to step in the door.

The other problem, Pazdur said, is pulling drugs from the market when confirmatory trials fail to verify clinical benefit. “If a study has failed … then I think companies need to step in and get these drugs off the market as quickly as possible – and many companies have done that,” he said.

Pazdur pointed to the breast cancer indication withdrawal of Avastin (bevacizumab) and the agency’s ongoing efforts to remove Makena (hydroxyprogesterone caproate injection) from the market as examples where the pathway has not worked as expected. “These represent challenges on how to make the system more agile, because a tremendous amount of resources have been spent on these hearings to withdraw a drug,” Pazdur said.

“It’s been ten years, I think, since the Avastin hearing and it’s still a nightmare for me what we’ve been through,” Pazdur said, noting recent congressional efforts to reform the expedited review pathway. to facilitate the withdrawal of medicinal products from the market.

“I think we are completely in agreement [accelerated approval] has been an extremely valuable pathway,” Califf said, noting her own experience with her mother taking a drug that had received fast-track approval after exhausting other treatment options. “She got two or three more years of good life because of that phone call and that rushed approval.”

Despite its positive experience with the pathway, Califf said the agency needed “more teeth” to pull approvals and force drugmakers to begin confirmatory trials before approval.

Califf then asked Pazdur about his observations on the trend of “offshoring” clinical trials in oncology.

“We want multi-regional trials that represent the main [International Council for Harmonisation] ICH regions around the world…we want adequate representation of patients from North America, Europe, Asia to be represented. We believe this gives us a spectrum of patient representation from our own country. We are not suggesting that all clinical trials should be done in the United States or that there is a percentage that should be done in the United States, but we want representation from all ICH regions,” said Pazdur.

He also noted the difference between a clinical trial conducted in other countries and a trial conducted in a single foreign country, referring to the recent Oncology Drug Advisory Committee (ODAC) meeting on the PD inhibitor sintilimab. -1 from Innovent, which largely dealt with the company’s China suitability. – sole clinical trial strategy. (RELATED: FDA officials and advisers question foreign-only clinical strategy, Regulatory guidance February 10, 2022)

Pazdur also provided details of a new initiative called Project Pragmatica that aims to simplify the process of conducting pragmatic trials. “It came to me like a flash when I saw a little trial done under Lung-MAP,” Pazdur said. The trial, which looked at ramucirumab plus pembrolizumab versus standard of care in second-line lung cancer, had some issues and it “wasn’t meant to be a registration trial.”

“I thought it would be a really great idea to try to do a pragmatic trial – again, preserving randomization – but making it as simple as possible. So what we discussed with the NCI is basically to really have only one endpoint of the trial and that’s overall survival… very minimal eligibility criteria and basically no safety reports other than for hospitalizations or toxicities that aren’t described in the safety evaluation criterion.

“We made these trials way too complicated…when I look at informed consents that are 20 pages long, no patient will read it,” Pazdur said.

However, Pazdur noted that the project would only be appropriate for “the right drug, the right situation” and when there is a known safety profile.

]]>
Saudi Arabia Ma’aden to export blue ammonia https://imphos.org/saudi-arabia-maaden-to-export-blue-ammonia/ Sat, 12 Nov 2022 04:56:49 +0000 https://imphos.org/saudi-arabia-maaden-to-export-blue-ammonia/ Saudi Arabian Mining Company (Ma’aden), the largest multi-product mining and metallurgical company in the Middle East, will export blue ammonia in an effort to support the global energy transition. The announcement was made by HRH Prince Abdulaziz Bin Salman, Saudi Minister of Energy, at the Saudi Green Initiative Forum, held on the sidelines of COP […]]]>

Saudi Arabian Mining Company (Ma’aden), the largest multi-product mining and metallurgical company in the Middle East, will export blue ammonia in an effort to support the global energy transition.

The announcement was made by HRH Prince Abdulaziz Bin Salman, Saudi Minister of Energy, at the Saudi Green Initiative Forum, held on the sidelines of COP 27 in Egypt.

Last month, Ma’aden was certified to export 138,000 tons of blue ammonia, one of the largest certified volumes in the world to date. The certifications were granted by TÜV Rheinland, an independent testing, inspection and certification agency based in Germany. The first shipment of 25,000 tonnes of Blue Ammonia will leave the Kingdom for South Korea this month.

As Ma’aden seeks to export minerals to support the energy transition, the company is also working to decarbonize its existing operations by implementing carbon capture technologies.

To this end, Ma’aden has signed a 20-year agreement with Gulf Cryo to build and operate a CO2 plant at its phosphate complex in Ras Al Khair. The new plant will capture 300,000 metric tons of CO2 emissions per year from Ma’aden’s three ammonia plants.

The CO2 will be used for industrial gas applications, replacing the use of fossil fuels, creating a circular carbon economy in Saudi Arabia.

Part of the CO2 will be distributed to International Maritime Industries (IMI), the largest shipyard in the MENA region. The rest will be used in industrial applications such as EOR (Enhanced Oil Recovery) and water desalination.

Commenting on the news, Robert Wilt, CEO of Ma’aden, said: “The decarbonization of ammonia production is an integral part of the global transition to net zero emissions. Ma’aden is well positioned to meet the growing demand for blue ammonia, exporting blue ammonia with minimal GHG emissions to markets around the world.

“The agreement with Gulf Cryo marks an important milestone on our journey to achieve net zero emissions by 2050 as Saudi Arabia’s National Mining Champion. This demonstrates our commitment to achieving the goals of the Saudi Green Initiative, in line with our aim to be a model for sustainable operations in the Kingdom. Carbon capture will further strengthen Ma’aden’s position as the world’s leading supplier of Blue Ammonia, a low-carbon approach to ammonia production,” he added.

Eng Hassan Al Ali, Executive Vice President, Phosphate, Ma’aden, added, “We are delighted to be one of the first certified producers of blue ammonia, with an agreement to export a significant volume soon after receiving our certificate. Additionally, our long-term agreement with Gulf Cryo will support Ma’aden’s sustainability strategy and our ambitions in the fertilizer market. By leveraging Gulf Cryo’s expertise, we will further decarbonize our fertilizer operations to help drive the global transition to net zero and improve our offering to the agricultural industry.

Amer Huneidi, President of Gulf Cryo, said, “We are delighted to have signed this partnership with Ma’aden. This agreement anchors our commitment to decarbonizing the region and supporting the Kingdom’s climate goals and localization goals.

Ammonia is an essential compound for several industries ranging from fertilizers to manufacturing. The ammonia market is valued at around $75 billion according to recent market research with a forecast CAGR of 8% through 2031. Blue ammonia is a compound composed of hydrogen and nitrogen that can be used to generate low-carbon energy, thus contributing to the energy transition. in a sustainable way.

Copyright 2022 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info).

]]>
Early signs point to this year’s flu season being the worst in years https://imphos.org/early-signs-point-to-this-years-flu-season-being-the-worst-in-years/ Tue, 08 Nov 2022 21:00:02 +0000 https://imphos.org/early-signs-point-to-this-years-flu-season-being-the-worst-in-years/ A weekly report released Friday by the US Centers for Disease Control and Prevention adds numbers to previous predictions of a troubling flu season. The number of reported hospitalizations as of Oct. 29 topped all recent years in the same week dating back to the 2010-11 season. Although not a direct count of cases, the […]]]>

A weekly report released Friday by the US Centers for Disease Control and Prevention adds numbers to previous predictions of a troubling flu season.

The number of reported hospitalizations as of Oct. 29 topped all recent years in the same week dating back to the 2010-11 season. Although not a direct count of cases, the number of people hospitalized with a virus such as influenza or COVID-19 reflects the health care burden of a disease and shows how many people are injured.

Experts have warned, however, that this season could produce more flu illnesses, depending on the severity of the situation in Australia – a country where flu viruses tend to develop first during the opposite winter season before to migrate to the northern hemisphere.

“It’s hard to anticipate the trends we’ll see each flu season, but we typically look to the southern hemisphere for clues,” said Dr. Brittany Mueller, internal medicine physician at Atlantic Medical Group. Primary Care. “Australia is monitoring its flu cases very carefully, and we know its flu season has started earlier than usual this year and has had a high number of cases.”

Additionally, mask-wearing and the public health precautions we’ve been taking since COVID-19[feminine] which also resulted in historically low flu seasons are starting to melt. And another respiratory disease known for its effects on young children and babies, respiratory syncytial virus (RSV) infectionalso causes waves of disease.

“Now that people are going out without masks, traveling a lot and having vacations again, going to restaurants and church services, and going back to school and the office, there are more opportunities for people. [flu] virus to circulate,” Dr. William Schaffner, medical director of the National Foundation for Infectious Diseases and professor of infectious diseases at Vanderbilt University Medical Center in Nashville, told AARP.

Each year, flu vaccines are changed to best reflect the circulating strains of the virus, including the formulations available that year. And because the bulk of flu season in the United States is probably still a few months away, getting vaccinated now will still protect you against serious illnesses. There are also some antiviral treatment options you should be aware of, especially if you are at higher risk for severe flu or flu complications.

Here’s what you need to know.

Should I get the flu shot?

Yes, most people should. The CDC issued a universal recommendation after the 2010-2011 flu season that everyone (with rare exceptions) should get the flu shot. There are different flu shots, depending on your age and other factors.

And if there’s one thing we’ve learned from the COVID-19 pandemic: what might be a week of being laid off for you might be a hospital stay or worse for someone another who catches the flu. Getting the flu shot minimizes your risk of serious illness, but may also reduce your risk of spreading the flu to others.

What are the treatments for the flu? Who is at high risk?

Most people who catch the flu pick up at home and can manage symptoms by staying hydrated, resting, and taking medication, if needed. But others are more susceptible to serious illness or complications from the flu, especially people aged 65 and over, very young children under 5, and people who are immunocompromised or have an underlying health condition. .

There are four antivirals approved by the United States Food and Drug Administration to treat influenza this season: oseltamivir phosphate (trade name Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (trade name commercial Xofluza). They have different treatment regimens and are approved for different age groups, but if you or your child are at high risk of flu complications you should contact your doctor as soon as you develop flu symptoms or think having been exposed, because antivirals seem to work better the sooner they are started — particularly two days after symptoms appear, according to the CDC. Healthy people at risk of developing a milder case of flu can also take an antiviral, but these treatments are specifically recommended by the CDC for people at higher risk.

If you are concerned about your risk of flu complications or think you are at higher risk, contact your doctor. But here are some groups of people at higher risk for flu complications and who should contact their doctor for further treatment, according to the CDC:

  • Older adults (usually 65 and over)
  • Children under 5 (children and babies under 2 are most at risk)
  • Pregnant women and those who have just given birth
  • People who live in retirement homes
  • People with lung or heart conditions, including asthma, COPD, and heart disease
  • People with kidney, liver, or blood disorders, including sickle cell disease
  • Those with metabolic disorders
  • People with diabetes or endocrine disorders
  • People with neurological or neurodevelopmental disorders
  • People with weakened immune systems

People of certain races and cultures are also more likely to get seriously ill from the flu. According to the CDC, Indigenous people are at higher risk for complications from the flu, including pneumonia and bronchitis.

How old do you have to be to get the flu shot?

Babies as young as 6 months old (and all older) can get the flu shot. The Centers for Disease Control and Prevention and the American Academy of Pediatrics say it’s safe to get the flu shot at the same time as the COVID-19 vaccine, which now includes the new COVID-19 booster.

Note that while it is safe to receive both vaccines at the same time, you may be more likely to experience mild, temporary side effects from the vaccine such as muscle aches if you receive both the COVID-19 vaccine and the vaccine against the flu at the same time, according to a study. .

A cup of tea with a box of tissues and medicine

Frank Grittke/Getty Images

Lily After: Flu Vaccine Side Effects: What’s Normal and What’s Worrying?

Which flu shot should I get?

The flu vaccine you receive will most likely depend on your age. Specific higher dose vaccines are recommended for adults 65 years and older, who may need an additional boost in immunity. All flu vaccines available this year are quadrivalent, meaning they are designed to protect against four different flu viruses.

There are different types of influenza vaccines, including standard-dose influenza vaccines for adults under 65, nasal vaccines containing live but weakened versions of the influenza virus for people ages 2 to 49, and stronger formulas for older adults.

The CDC does not have a specific recommendation for most people under age 65. But there might be special considerations or advice for other adults, including people who are pregnant, those with a history of Guillain-Barré syndrome, and people who have had a serious illness. allergic reaction to a vaccine in the past, according to Mueller.

If you are over 65: The CDC recommends that you receive either the Fluzone High-Dose Quadrivalent vaccine, the Flublok Quadrivalent recombinant influenza vaccine, or the Fluad Quadrivalent adjuvanted influenza vaccine, if possible. These flu vaccines have been shown to elicit a more robust immune response in older adults.

When to get the flu shot

The CDC recommends most people get it in September or October, but getting one after October will likely still be effective in protecting you before the peak of flu season, which usually begins to peak around December and continues. until March.

“It takes about two weeks to develop the antibodies, which will last about six months,” Mueller said. “This will get us through most of the winter months when the flu tends to be prevalent in the northern hemisphere.”

Where to get the flu shot

The flu vaccination campaign is different from the campaign for COVID-19 vaccines, which are free for everyone because they were paid for by the federal government and strategically available through a vaccine search website.

But you should still be able to find a flu shot relatively easily. If you have an attending physician, you can get one in their practice. If you don’t have a health care provider, you can call a pharmacy or health clinic near you to see if one is available. They might ask your age to see if they have the recommended vaccine in stock for you.

Note that when you see a “free flu shot” ad at a pharmacy like this, it usually means free for most insurance plans. If you have health insurance (including Medicaid), you should be able to find a free or discounted flu shot. However, if you decide to make a doctor’s appointment, the office visit might be an added expense, even if the flu shot was free.

How much does a flu shot cost without insurance?

If you are completely uninsured, you may still be able to get a free flu shot from your local health department or community clinic, which often hold pop-up events at the start of flu season. . You can also pay out of pocket at a doctor or pharmacy – the cost of the vaccine itself usually ranges from $20 to $75.

The information in this article is for educational and informational purposes only and is not intended to constitute medical or health advice. Always consult a physician or other qualified health care provider with any questions you may have about a medical condition or health goals.

]]>
Animal with first ever skeleton revealed by 500 million year old fossils https://imphos.org/animal-with-first-ever-skeleton-revealed-by-500-million-year-old-fossils/ Sat, 05 Nov 2022 21:27:14 +0000 https://imphos.org/animal-with-first-ever-skeleton-revealed-by-500-million-year-old-fossils/ Scientists have been able to solve a long-standing puzzle in the evolution of life on earth by revealing the appearance of the first animals to make skeletons thanks to a surprisingly well-preserved collection of fossils dating back 500 million years that has been found in eastern Yunnan. Province, China. sudden onset In a geological flash, […]]]>

Scientists have been able to solve a long-standing puzzle in the evolution of life on earth by revealing the appearance of the first animals to make skeletons thanks to a surprisingly well-preserved collection of fossils dating back 500 million years that has been found in eastern Yunnan. Province, China.

sudden onset

In a geological flash, between 550 and 520 million years ago, during the Cambrian Explosion, the first animals to develop strong, hard skeletons appear in the fossil record. Many of these ancient fossils are just simple hollow tubes that range in length from several millimeters to a few centimeters.

Due to the lack of preservation of the soft parts necessary to distinguish them as belonging to the main groups of animals still alive today, it was almost impossible to determine what type of organisms made these skeletons.

Gangtoucunia Aspera

There are four specimens of Gangtoucunia aspera in the new 514-million-year-old fossil collection that still have their soft tissues, such as their intestines and mouthparts, intact. These prove that the mouth of this species was lined with a ring of smooth, unbranched tentacles 5 mm long. These were probably used to catch and sting prey, such as small arthropods.

Fossils also demonstrate that Gangtoucunia had a blind-ended intestine partitioned off by an internal cavity that ran the full length of the tube and was only open at one end.

These characteristics are present only in contemporary jellyfish, anemones and their close relatives, which are extremely rare soft-bodied organisms in the fossil record. Research demonstrates that these primitive creatures were among the first to develop the hard skeletons that make up the majority of the fossil record.

According to the researchers, with a strong tubular structure rooted in the underlying substrate, Gangtoucunia would have resembled polyps of modern scyphozoan jellyfish. The tentacle’s mouth would have extended past the tube but could have been retracted inside to escape predators.

The Gangtoucunia tube was made of calcium phosphate, a hard mineral that also makes up human teeth and bones, unlike the living polyps of jellyfish. It became less common for animals to use this material to build skeletons over time.

Key Piece of Problematic Fossils

Dr Luke Parry, the study‘s corresponding author from the University of Oxford’s Department of Earth Sciences, said these mysterious tubes are usually seen in groups of hundreds, but until recently there was no There was no way to classify them, so they were considered “problematic” fossils. These remarkable new specimens have helped firmly anchor a crucial piece of the evolutionary puzzle.

Also Read: Scientists Voucher for Plausibility of Loch Ness Monster’s Existence After Fossil Analysis

Not a worm but a cnidarian

According to the University of Oxford, the new specimens unequivocally show that, contrary to what had previously been assumed for related fossils, Gangtoucunia was never related to annelid worms such as earthworms, polychaetes and their relatives. It is now evident that the annelids have segmented bodies with a transverse separation from the body, whereas Gangtoucunia had a smooth exterior and a longitudinally divided intestine.

The fossil was discovered in Kunming, in the eastern province of Yunnan, China, in the district of Gaoloufang. The fossil was discovered at a location in Kunming, located in eastern Yunnan province, China, in the village of Gaoloufang. Anaerobic or oxygen-poor conditions, like those in this area, limit the presence of bacteria that typically break down soft tissue in fossils.

Guangxu Zhang, a doctoral student who discovered and collected the specimens, was surprised and unsure of what they were when he first noticed the pink soft tissue at the top end of a Gangtoucunia tube.

He discovered three more specimens bearing soft tissue preservation the following month, which was extremely exciting and caused him to reconsider the affinities of Gangtoucunia. He realized that Gangtoucunia is a cnidarian when he noticed that its soft tissues, especially the tentacles, clearly show that it is not a priapulid-like worm as earlier studies had suggested. Instead, it looks more like coral.

primitive jellyfish

Although the fossil unequivocally demonstrates that Gangtoucunia was a prehistoric jellyfish, it is still possible that some early species of tubular fossils may have had very different appearances. The research team has previously discovered well-preserved tube fossils in Cambrian rocks in Yunnan province that could be classified as priapulids or marine worms, lobopods, which are paired-legged worms closely related to modern arthropods. , and annelids.

Xiaoya Ma, a co-corresponding author from Yunnan University and the University of Exeter, said the Cambrian appears to have seen an increase in the prevalence of tube-dwelling lifeforms, which may have been an adaptive response. to the increased predation pressure of the Early Cambrian. This study shows that excellent soft tissue preservation is essential for our understanding of these extinct animals, reports Phys Org.

The Proceedings of the Royal Society B published the article earlier this month.

Related article: Study: Abu Dhabi’s fossil dunes are created by climate change 200,000 years ago

© 2022 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

]]>
Early amino acids in extremely preterm infants and neurological disorders at 2 years https://imphos.org/early-amino-acids-in-extremely-preterm-infants-and-neurological-disorders-at-2-years/ Wed, 02 Nov 2022 21:08:23 +0000 https://imphos.org/early-amino-acids-in-extremely-preterm-infants-and-neurological-disorders-at-2-years/ Summary Background It is unknown whether higher parenteral amino acid intake improves outcomes in extremely low birth weight infants. Methods Download a PDF of the research summary. In this multicenter, parallel-group, double-blind, randomized, placebo-controlled trial, we assigned infants with a birth weight of less than 1000 g in 8 neonatal intensive care units to receive […]]]>

Summary

Background

It is unknown whether higher parenteral amino acid intake improves outcomes in extremely low birth weight infants.

Methods

Download a PDF of the research summary.

In this multicenter, parallel-group, double-blind, randomized, placebo-controlled trial, we assigned infants with a birth weight of less than 1000 g in 8 neonatal intensive care units to receive amino acids at a dose of 1 g per day (group intervention) or placebo in addition to usual nutrition for the first 5 days after birth. The primary outcome was neurodeficiency-free survival, assessed using the Bayley Scale for Infant and Toddler Development and neurological examination at 2 years, corrected for gestational age at birth. The secondary endpoints were the components of the primary endpoint as well as the presence or absence of neonatal disorders, growth rate and nutritional intake.

Results

We recruited 434 infants (217 per group) in this trial. Neurological disease-free survival was observed in 97 of 203 children (47.8%) in the intervention group and in 102 of 205 (49.8%) in the placebo group (adjusted risk ratio, 0.95; confidence interval at 95%). [CI], 0.79 to 1.14; p=0.56). Death before the age of 2 years occurred in 39 of 217 children (18.0%) in the intervention group and 42 of 217 (19.4%) in the placebo group (adjusted relative risk, 0.93; at 95%, 0.63 to 1.36); neurological disability occurred in 67 of 164 children (40.9%) in the intervention group and 61 of 163 (37.4%) in the placebo group (adjusted relative risk, 1.16; 95% CI, 0. 90 to 1.50). Neurological impairment was moderate to severe in 27 children (16.5%) in the intervention group and 14 (8.6%) in the placebo group (adjusted relative risk, 1.95; 95% CI, 1. 09 to 3.48). More children in the intervention group than in the placebo group had a patent ductus arteriosus (adjusted relative risk, 1.65; 95% CI, 1.11 to 2.46). In a post hoc analysis, refeeding syndrome occurred in 42 of 172 children in the intervention group and 26 of 166 in the placebo group (adjusted relative risk, 1.64; 95% CI, 1.09 to 2.47 ). Eight serious adverse events occurred.

conclusion

In extremely low birth weight infants, extra parenteral amino acids at a dose of 1 g daily for 5 days after birth did not increase the number of survivors without neurological damage at 2 years. (Funded by the New Zealand Health Research Council and others; Australian New Zealand ProVIDe Clinical Trials Registry Number, ACTRN12612001084875.)

Digital object thumbnailQUICK SUMMARY OF THE VIDEO
Early amino acids in extremely premature babies
01:43

]]>
Birds are good for our mental health, study finds https://imphos.org/birds-are-good-for-our-mental-health-study-finds/ Thu, 27 Oct 2022 21:51:09 +0000 https://imphos.org/birds-are-good-for-our-mental-health-study-finds/ October 27, 2022 — Birdsong has always delighted poets, who have often written about its calming effect. Now a new study says birdsong is good for mental health. Scholars from King’s College London found that hearing birds, seeing them and having ordinary encounters with birds improved the mood of people with depression, as well as […]]]>

October 27, 2022 — Birdsong has always delighted poets, who have often written about its calming effect. Now a new study says birdsong is good for mental health.

Scholars from King’s College London found that hearing birds, seeing them and having ordinary encounters with birds improved the mood of people with depression, as well as the general population.

The study tracked around 1,300 people through their daily encounters with birds over the past year using a smartphone app called Urban Mind. People were in Britain, Europe, the United States, Australia and China.

Using the app, study participants recorded how they felt, if they were stressed or happy, if they could see trees, and if they could see or hear birds.

Average mental well-being scores increased when people saw or heard birds, even for people who had previously been diagnosed with depression.

“We need to create and support environments, especially urban environments, where bird life is a constant feature. To have a healthy bird population, you also need plants, you also need trees. We need to nurture the whole ecosystem within our cities,” said Andrea Mechelli, a professor at King’s College London. The Guardian.

He said it was important to learn that birds have a positive effect on people with depression because many treatments “that help so-called ‘healthy people’ don’t work for people with depression. mental health problems”.

Adrian Thomas, author of Guide to Birdsong from the Royal Society for the Protection of Birdssaid the report makes sense, as people generally report that birdsong brings feelings of joy.

“It’s anchored somewhere deep in our psyche,” he said. “It is associated with spring, renewal and the good times to come… We must deal with this crisis of nature and ensure that nature does not fall silent.”

]]>
When is the best time to take vitamin D? https://imphos.org/when-is-the-best-time-to-take-vitamin-d/ Tue, 25 Oct 2022 05:42:44 +0000 https://imphos.org/when-is-the-best-time-to-take-vitamin-d/ You may not realize that for most of us there is actually a best time to take vitamin D. This is because in most of the world we experience climate fluctuation and the amount of sunlight we are exposed to. the year. Since vitamin D is known as the “sunshine vitamin”, it is important that […]]]>

You may not realize that for most of us there is actually a best time to take vitamin D. This is because in most of the world we experience climate fluctuation and the amount of sunlight we are exposed to. the year. Since vitamin D is known as the “sunshine vitamin”, it is important that we get enough exposure to UV rays to ensure that we do not develop deficiencies, as the sun is our main source of vitamin D.

Vitamin D is not only important on its own, it also helps us absorb calcium and phosphorus, which are the most abundant minerals found in our skeleton. If we have vitamin D deficiency, we also expose ourselves to diseases related to calcium and phosphorus deficiency, which mainly impact our bone health.

If you’re worried about getting enough vitamin D during the colder months, you might want to start taking the best vitamin d supplements to support your health.

person taking supplements

(Image credit: Getty)

What is Vitamin D?

]]>
Benzoproperine Phosphate Market Size and Forecast https://imphos.org/benzoproperine-phosphate-market-size-and-forecast/ Fri, 21 Oct 2022 15:17:55 +0000 https://imphos.org/benzoproperine-phosphate-market-size-and-forecast/ New Jersey, United States – “Benzoproperine Phosphate Market Overview, Forecast 2028” is recently published by Verified Market Reports. Analysts and researchers conducted large-scale primary and secondary research using various methodologies such as Porter’s Five Forces and PESTLE analysis. The key trends and opportunities that may emerge in the near future have been discussed in the […]]]>

New Jersey, United States – Benzoproperine Phosphate Market Overview, Forecast 2028” is recently published by Verified Market Reports. Analysts and researchers conducted large-scale primary and secondary research using various methodologies such as Porter’s Five Forces and PESTLE analysis. The key trends and opportunities that may emerge in the near future have been discussed in the Benproperine Phosphate market report. A detailed analysis of the factors positively influencing growth has been made by the professionals. In addition, factors that may pose key challenges for participants are discussed in the Benproperine Phosphate market report. The Benproperine Phosphate research report emphasizes on the key trends and opportunities that may emerge in the near future that will have a positive impact on the overall growth of the industry. The key drivers fueling the growth are also discussed in the Benproperine Phosphate report. Additionally, challenges and restraining factors that may restrain growth in the coming years are highlighted by analysts to prepare manufacturers for future challenges in advance.

Additionally, market revenue based on region and country is provided in the Benproperine Phosphate report. The report’s authors also shed some light on common trading tactics that players are adopting. Major Benproperine Phosphate market players and their comprehensive profiles are included in the report. In addition to these, investment opportunities, recommendations, and trends currently emerging in the Benproperine Phosphate market are mapped by the report. Through this report, key players in the Benproperine Phosphate market will be able to make wise decisions and plan their strategies accordingly to stay one step ahead.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketreports.com/download-sample/?rid=136854

Key Players Mentioned in the Benproperine Phosphate Market Research Report:

The competitive landscape is a critical aspect that every key player must be aware of. The report sheds light on the competitive scenario of the Benproperine Phosphate Market to know the competition at national and global level. Market experts have also provided an outline of each major Benproperine Phosphate market player, considering the key aspects such as areas of operation, production, and product portfolio. Moreover, the companies in the report are studied based on key factors such as company size, market share, market growth, revenue, production volume, and profit.

Toronto Research Chemicals, 3B Scientific, AlliChem, Waterstone Technology, J&K SCIENTIFIC, BeiJing Hwrk Chemicals, XiaoGan ShenYuan ChemPharm, Hangzhou Yuhao Chemical Technology, Wuhan Fortuna Chemical, Cheng Du Micxy Chemical, Nanjing Sunlida Biological Technology

Benzoproperine Phosphate Market Segmentation:

Global Benproperine Phosphate Market By Type:

• Type I
• Type II
• Type III
• Type IV

Global Benproperine Phosphate Market by Applications:

• Chemical reagents
• Pharmaceutical intermediates
• Other

Our market analysts are experts at in-depth segmentation of the Benproperine Phosphate Market and thoroughly assessing the growth potential of each segment studied in the report. From the beginning of the research study, the segments are compared on the basis of consumption and growth rate for a review period of nine years. The segmentation study included in the report offers a brilliant analysis of the Benproperine Phosphate market, considering the market potential of the various segments studied. It helps market players to focus on high growth areas of the Benproperine Phosphate market and plan powerful business tactics to secure a position of strength in the industry.

The Benproperine Phosphate market study is incomplete without regional analysis, and we are well aware of this. That is why the report includes a complete and all-inclusive study that focuses solely on the geographical growth of the Benproperine Phosphate Market. The study also includes accurate estimates on the growth of the market at the global, regional and country levels. It helps you understand why some regional markets are thriving while others are experiencing declining growth. It also allows you to focus on geographies that have the potential to create lucrative leads in the near future.

Inquire for a discount on this Premium Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=136854

What to expect in our report?

(1) A comprehensive section of the Benproperine Phosphate market report is devoted to market dynamics, which includes influencing factors, market drivers, challenges, opportunities, and trends.

(2) Another large section of the research study is reserved for the regional analysis of the Benproperine Phosphate Market where important regions and countries are assessed for their growth potential, consumption, market share, and others vital factors indicating their market growth.

(3) Players can use the competitive analysis provided in the report to develop new strategies or refine their existing strategies to meet market challenges and increase their share of the Benproperine Phosphate market.

(4) The report also examines the competitive situation and trends and sheds light on company expansions and ongoing mergers and acquisitions in the Benproperine Phosphate market. Moreover, it sheds light on the market concentration rate and market shares of top three and top five players.

(5) Readers are provided with the findings and conclusion of the research study provided in the Benproperine Phosphate Market report.

Key questions answered by the report:

(1) What are the growth opportunities for new entrants in the Benproperine Phosphate industry?

(2) Who are the key players operating in the Benproperine Phosphate Market?

(3) What are the key strategies participants are likely to adopt to increase their share in the Benproperine Phosphate industry?

(4) What is the Competitive Situation in the Benproperine Phosphate Market?

(5) What are the emerging trends that may be influencing the growth of the Benproperine Phosphate market?

(6) Which product type segment will have a high CAGR in the future?

(7) Which application segment will grab a good share of Benproperine Phosphate industry?

(8) Which region is lucrative for manufacturers?

For more information or query or customization before buying, visit @ https://www.verifiedmarketreports.com/product/global-benproperine-phosphate-market-report-2019-competitive-landscape-trends-and-opportunities/

Most Popular Reports

Global Food Humectants Market Size and Forecast

Global Benproperine Phosphate Market Size and Forecast

Global Filling Masterbatch Market Size and Forecast

Global 4D printing market size and forecast

Global Advanced Fiber Based Gaskets Market Size and Forecast

Global Galactomannan Gum Market Size and Forecast

Global Metal 3 Parts Aerosol Market Size and Forecast

Global Offshore Crane Market Size and Forecast

Global Liquid Phase Deposition Market Size and Forecast

Global Chiti-Chitosan Trade Market Size and Forecast

About Us: Verified Market Reports

Verified Market Reports is a leading global research and advisory company serving over 5000 global clients. We provide advanced analytical research solutions while delivering information-enriched research studies.

We also provide insight into the strategic and growth analytics and data needed to achieve business goals and critical revenue decisions.

Our 250 analysts and SMEs offer a high level of expertise in data collection and governance using industry techniques to collect and analyze data on over 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Our research spans a multitude of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage, and more. Having served many Fortune 2000 organizations, we bring a wealth of reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

E-mail: sales@verifiedmarketreports.com

Website: – https://www.verifiedmarketreports.com/

]]>
Li-ion battery market for all electric vehicles in depth https://imphos.org/li-ion-battery-market-for-all-electric-vehicles-in-depth/ Mon, 17 Oct 2022 19:45:00 +0000 https://imphos.org/li-ion-battery-market-for-all-electric-vehicles-in-depth/ Li-ion battery market for all electric vehicles Latest industrial growth study of the Li-ion Batteries for All Electric Vehicles Market 2022-2028. A detailed study accumulated to offer up-to-the-minute insights into acute characteristics of the Li-ion Battery For All Electric Vehicles Market. The report contains different market forecasts related to revenue size, production, CAGR, consumption, gross […]]]>

Li-ion battery market for all electric vehicles

Latest industrial growth study of the Li-ion Batteries for All Electric Vehicles Market 2022-2028. A detailed study accumulated to offer up-to-the-minute insights into acute characteristics of the Li-ion Battery For All Electric Vehicles Market. The report contains different market forecasts related to revenue size, production, CAGR, consumption, gross margin, price, and other important factors. While emphasizing the major driving and restraining forces of this market, the report also offers a comprehensive study of the future market trends and developments. It also examines the role of major market players involved in the industry, including their company overview, financial summary, and SWOT analysis.

Key players covered in this report: A123 Systems, AESC, Blue Energy, BYD, Coslight, Hitachi, Johnson Matthey, LG Chem, Panasonic, SAFT, Sinopoly Battery, Tianjin Lishen Battery, Toshiba, China BAK battery, Deutsche ACCUmotive, Johnson Controls , Samsung SDI and Sony

The Li ion Battery for All Electric Vehicles market study ensures you stay/remain advised higher than your competitors. With structured tables and figures examining Li-ion Battery for all Electric Vehicles, the research document provides you with top product, submarkets, sales size and forecast to 2027. Comparatively, it also ranks emerging as well as industry leaders. Click to Get Sample PDF of Li-ion Battery for All Electric Vehicles Market (Including Full TOC, Table and Figures) @ https://www.htfmarketreport.com/sample-report/3665661-li-ion-battery-for-all-electric-vehicles-market-1

This study also covers company profiling, product specifications and picture, sales, market share and contact information of various regional, international and local vendors of the Li-ion Battery for All Electric Vehicles market. The market proposition is changing frequently with increasing scientific innovation and M&A activity in the industry. Additionally, many local and regional vendors offer specific application products for various end users. New candidate traders in the market find it difficult to compete with international suppliers based on reliability, quality and modernity of technology.

Read the detailed index of the full research study at @ https://www.htfmarketreport.com/reports/3665661-li-ion-battery-for-all-electric-vehicles-market-1

The titled segments and sub-sections of the market are illuminated below:
In-Depth Analysis of Li-ion Battery for All Electric Vehicles Market Segment by Types:, Lithium-Manganese Oxide Battery, Lithium Iron Phosphate Battery, LiNiMnCo (NMC) Battery, and Lithium-Titanate Battery
Detailed analysis of the Li-ion Battery for All Electric Vehicles market segments by applications: HEV, PHEV and BEV

Top Key Market Players: A123 Systems, AESC, Blue Energy, BYD, Coslight, Hitachi, Johnson Matthey, LG Chem, Panasonic, SAFT, Sinopoly Battery, Tianjin Lishen Battery, Toshiba, China BAK battery, Deutsche ACCUmotive, Johnson Controls, Samsung SDI and Sony

Regional Analysis For Li-ion Battery For All Electric Vehicles Market:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, Netherlands, Bas, in Poland, Czech Republic, Slovakia, Hungary and Romania)
• North America (United States, Canada and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (Saudi Arabia, United Arab Emirates, South Africa)

In addition, the years considered for the study are as follows:
Historic year – 2018-2021
Base year – 2021
Forecast period** – 2022 to 2030 [** unless otherwise stated]

**Furthermore, it will also include the opportunities available in the micro markets for the stakeholders to invest, a detailed analysis of the competitive landscape and product services of key players.

Buy the latest edition of Market Research now @ https://www.htfmarketreport.com/buy-now?format=1&report=3665661

The key points of the Li-ion Battery for All Electric Vehicles market report:
– Detailed consideration of the All Electric Vehicle Li-ion Battery market particular drivers, trends, restraints, restraints, opportunities, and major micro markets.
– Comprehensive assessment of all prospects and threats in the
– In-depth study of industry strategies for growth of the Li-ion Battery for All Electric Vehicles market-leading players.
– Li ion battery for all electric vehicles on the market latest innovations and major procedures.
– Favorable drop inside the vigorous high-tech and remarkable latest market trends of the market.
– Conclusive study about the growth plot of Li-ion Battery for All Electric Vehicles Market for forthcoming years.

What to expect from this report on Li-ion Battery for All Electric Vehicles Market:
1. A comprehensive synopsis of several area breakdowns and summary product types popular in the Li-ion Battery for All Electric Vehicles market.
2. You can repair your growing industry databases when you have information about cost of production, cost of products and cost of production for the next coming years.
3. In-depth break-in assessment for new companies to enter the Li-ion battery for all electric vehicles market.
4. How exactly do top companies and mid-level companies earn revenue in the market?
5. Complete research on overall development within Li-ion Battery for All Electric Vehicles Market that helps you choose launch and review growths of the product.

Inquire for customization in Report @ https://www.htfmarketreport.com/enquiry-before-buy/3665661-li-ion-battery-for-all-electric-vehicles-market-1

Detailed TOC of Li-ion Battery for All Electric Vehicles Market Research Report-

– Introduction of Li-ion battery for all electric vehicles and market overview
– Li-ion battery market for all electric vehicles, by application [HEVs, PHEVs & BEVs]
– Industry Chain Analysis of Li-ion Battery for All Electric Vehicles
– Li-ion battery market for all electric vehicles, by type [, Lithium Ion Manganese Oxide Battery, Lithium Iron Phosphate Battery, LiNiMnCo (NMC) Battery & Lithium?titanate Battery]
– Industry Manufacture, Consumption, Export, Import by Regions (2015-2020)
– Industry value ($) by region (2015-2020)
– Li-ion Battery for All Electric Vehicles Market Status and SWOT Analysis by Regions
– Major region of the Li-ion battery market for all electric vehicles
i) Sale of Li-ion batteries for all electric vehicles
ii) Li-ion Battery for All Electric Vehicle Revenue and Market Share
– List of main companies
– Conclusion

Thank you for reading this article; you can also get individual chapter wise section or region wise report version like North America, MINT, BRICS, G7, Western/Eastern Europe or Southeast Asia. In addition, we can offer you personalized research services, as HTF MI holds a database repository that includes public organizations and millions of private companies with expertise in various fields of industry.

Contact us :
Craig Francis (Public Relations and Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Phone: +1 (434) 299-0043
sales@htfmarketreport.com

About the Author:
HTF Market Intelligence consulting is in a unique position to empower and inspire with research and advisory services to empower businesses with growth strategies, delivering services with extraordinary depth and breadth of thought leadership, research, tools, events and experience that help decision-making.

This press release was published on openPR.

]]>